한빛사논문
- 조회261
Hee Byung Koh M.D. 1,2, Hyung Woo Kim M.D. 1, Young Su Joo M.D., Ph.D. 3, Chan-Young Jung M.D. 4, Hyo Jeong Kim M.D. 5, Tae Ik Chang M.D., Ph.D. 6, Jung Tak Park M.D., Ph.D. 1, Tae-Hyun Yoo M.D., Ph.D. 1, Shin-Wook Kang M.D., Ph.D. 1, Seung Hyeok Han M.D., Ph.D. 1
1Department of Internal Medicine, College of Medicine, Institute of Kidney Disease Research, Yonsei University, Seoul, Republic of Korea
2Division of Nephrology, Department of Internal Medicine, Catholic Kwandong University International Saint Mary's Hospital
3Division of Nephrology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Republic of Korea
4Department of Internal Medicine, Asan Medical Center and University of Ulsan College of Medicine, Seoul, Korea
5Division of Nephrology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
6Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea
Corresponding Author: Seung Hyeok Han M.D., Ph.D
Abstract
Rationale & objective: Many studies have reported polyunsaturated fatty acids (PUFA) as significant predictors of cardiovascular disease, but little is known about the relationship between PUFA levels and chronic kidney disease (CKD). This study explored this relationship among individuals with and without CKD.
Study design: Prospective observational cohort study.
Setting & participants: 78,950 participants without CKD (cohort 1) and 7,233 participants with CKD (cohort 2) in the UK Biobank Study with PUFA levels measured between 2007 and 2010.
Exposures: Percentage of plasma PUFA, omega-3 fatty acid (FA), omega-6 FA, docosahexaenoic acid (DHA), and linoleic acid relative to total fatty acid.
Outcomes: Incident CKD for cohort 1 and incident kidney failure requiring replacement therapy (KFRT) for cohort 2.
Analytical approach: Cox proportional hazards regression analyses, including a cause-specific competing risk model.
Results: In cohort 1, individuals with higher quartiles of plasma PUFA levels had healthier lifestyles and fewer comorbidities. During 841,007 person-years of follow-up (median 11.9 years), incident CKD occurred in 4.5% of participants (incidence rate, 39.1 per 10,000 person-years). For incident CKD in cohort 1, the adjusted cause-specific hazard ratios (HR) (95% CIs) for quartiles 2, 3, and 4 were 0.83 (0.75-0.92), 0.85 (0.76-0.96), 0.71 (0.62-0.82), respectively, compared with quartile 1. This inverse relationship was consistently observed for all PUFA types. In cohort 2, although, total PUFA levels were not associated with KFRT, higher PUFA subtype levels of DHA were associated with a lower risk of KFRT.
Limitations: Observational design and limited generalizability to individuals with higher disease severity; no data on eicosapentaenoic acid.
Conclusions: Among individuals without CKD, higher plasma PUFA levels and all four PUFA components were associated with a lower risk of incident CKD. In individuals with CKD, only the omega-3 component of PUFA, DHA, was associated with a lower risk of KFRT.
논문정보
- Research article
- 2024년 02월 (BRIC 등록일 2024-03-11)
- 국내 연구진
- 의약학 > 응용의학
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기
